Prognosis in 550 Cases With Renal Cell Carcinoma

Satomi, Yoshiaki; Fukuda, M; Hosaka, Masahiko; Kondo, Iichiro; Yoshimura, Sadao; Fukushima, S; Ida, Tokio; Hirokawa, Makoto; Morita, Takashi; Furuhata, Akihiko; Kumagai, Harumi; Shiozaki, Hiroshi; Ishizuka, Eiichi; Miyai, Keikoku; Sugita, Y.; Fukuoka, Hiroshi; Sasaki, Koichi; Kodaira, Teruo; Nakahashi, Mitsuru

doi:10.5980/jpnjurol1928.79.5_853

Cited by 8 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Satomi et al 9 found no significant difference in 10-year survival between these groups. Satomi et al 9 found no significant difference in 10-year survival between these groups.…”

Section: Growth Typementioning

confidence: 89%

“…The tumor growth type was classfied according to Satomi et al 9 into two groups; a rapidgrowth type (C-reactive protein [CRP]-positive and fever preoperatively) and slow-growth type (CRP-negative, without fever preoperatively). Eight indices were selected as prognostic factors for long term survival; sex, age, clinical stage, tumor size, tumor growth type, pathological grade, tumor cell type, and local invasion (capsular invasion and microvascular invasion).…”

Section: Methodsmentioning

confidence: 99%

“…Survival curves for RCC patients with the late-stage disease (ജ Robson III; n ϭ 20). [9][10][11][12][13][14] Other authors, 3 using multivariate analysis, found distant metastasis to be the most significant determinant of survival. [9][10][11][12][13][14] However, a recent clinical study reported a 5-year survival rate of 77.8%.…”

Section: Clinical Stagementioning

confidence: 99%

“…Satomi et al 9 reported that 5-year survival rates for patients with tumors measuring 50 mm or less 50-100 mm, and 100 mm or more were 65%, 42%, and 42%, respectively. On the other hand, Nativ et al et al 16 showed that the parameters they examined, including tumor grade and ploidy, did not vary significantly among tumor size subgroups (ഛ5 cm and Ͼ5 cm) and therefore, that tumors pathologically limited to the kidney did not vary in prognosis according to size.…”

Section: Tumor Sizementioning

confidence: 99%

See 3 more Smart Citations

Multivariate analysis of clinicopathologic factors and the efficacy of postoperative IFN-γ adjuvant therapy in 115 patients with renal cell carcinoma

et al. 1999

View full text Add to dashboard Cite

“…Satomi et al 9 found no significant difference in 10-year survival between these groups. Satomi et al 9 found no significant difference in 10-year survival between these groups.…”

Section: Growth Typementioning

confidence: 89%

Section: Methodsmentioning

confidence: 99%

Section: Clinical Stagementioning

confidence: 99%

Section: Tumor Sizementioning

confidence: 99%

See 2 more Smart Citations

Multivariate analysis of clinicopathologic factors and the efficacy of postoperative IFN-γ adjuvant therapy in 115 patients with renal cell carcinoma

et al. 1999

View full text Add to dashboard Cite

“…The clinicopathologic factors were examined based on the criteria of the Japanese Urological Association 8 . The tumor growth type was divided by Satomi et al into two groups consisting of a rapid growth type (acute phase reactant positive and fever preoperatively) and a slow growth type (acute phase reactant negative without fever preoperatively) 9 …”

Section: Methodsmentioning

confidence: 99%

Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: The influence of neoadjuvant treatment

et al. 2001

View full text Add to dashboard Cite

Background: This study was conducted in order to clarify whether histopathologic analysis of factor thymidine phosphorylase (TP) and Factor VIII could be a useful predictor of postoperative recurrence in localized renal cell carcinoma. Therefore, the relationship between tumor infiltrated lymphocytes (TIL) and both TP and Factor VIII was studied. Method: Of the 71 patients who underwent surgery, 54 patients had no neoadjuvant therapy (group 1), 10 patients were preoperatively administered IFN-g (group 2), and the remaining seven patients preoperatively received IFN-g and transarterial embolization (group 3). Both TP and Factor VIII immunostaining were performed on formalin-fixed, paraffin-embedded archival tissue from 71 renal cell carcinoma specimens, while TIL immunostaining was performed on frozen sections. Positive immunostaining was quantitatively scored by a computer-assisted digital image analysis. For TIL, positive results were semiquantitatively scored. Results: A significant difference in the recurrence-free rate was recognized for Groups 1, 2 and 3 (P < 0.05). Therefore, the median TP-positive rate (PR), VIII-PR, number of microvessels and positive mean vascular area levels were investigated, between the recurrence cases (n = 6) and the recurrence-free cases (n = 11). Only the TP-PR levels showed a significant difference among them (P = 0.044). In regards to the neoadjuvant cases, a significant correlation was observed between both VIII-PR and CD4 (r = 0.815) as well as between VIII-PR and CD11b (r = 0.756). Conclusion:There was no clear evidence that the neoadjuvant treatment would increase the recurrence-free survival in patients with localized renal cell carcinoma. TP-PR might be a predictor of postoperative recurrence in patients with localized renal cell carcinoma.

show abstract

Interleukin-6 in Renal Cell Carcinoma

et al. 1992

View full text Add to dashboard Cite

We studied interleukin-6 production in 4 human renal cell carcinoma cell lines and measured the serum level in 71 patients with renal cell carcinoma, thus, clarifying a relationship between interleukin-6 secretion and an occurrence of the paraneoplastic syndrome in the carcinoma. Interleukin-6 was produced by 3 cell lines and detected in 25% of the patients. The level of interleukin-6 did not directly correlate with tumor volume and the differentiation grade of the carcinoma. However, the positive rate increased with progression of the stage. The serum level affected the 5-year survival of patients without distant metastasis. When serum interleukin-6 was elevated patients had a significantly higher frequency of unexplained fever and an elevation of acute phase proteins. These results suggest that some renal cell carcinomas can produce interleukin-6 and this cytokine is responsible for several paraneoplastic syndromes in the carcinoma.

show abstract

Prognosis in 550 Cases With Renal Cell Carcinoma

Cited by 8 publications

References 0 publications

Multivariate analysis of clinicopathologic factors and the efficacy of postoperative IFN-γ adjuvant therapy in 115 patients with renal cell carcinoma

Multivariate analysis of clinicopathologic factors and the efficacy of postoperative IFN-γ adjuvant therapy in 115 patients with renal cell carcinoma

Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: The influence of neoadjuvant treatment

Interleukin-6 in Renal Cell Carcinoma

Contact Info

Product

Resources

About